Investment strategist. Never ask me why: 'T.A.' only

Update: ARGEN-X

29/09/20 ——————————————————————————————————————– 8/06/20 Argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. Fair value: 177.50€ Premium: 16% Average yearly return: +55% Buy cheap around: +172.50€ On June the 1rst ARGX announced the closing of its previously announced global offering of…

Continue reading